Document |
Document Title |
WO/2021/189153A1 |
The present invention provides for use of fenretinide, fenretinide analog or pharmaceutically acceptable salts for the preparation of medicaments useful for the treatment of SARS-coronavirus, ARDS and SARS-coronavirus associated pneumoni...
|
WO/2021/189750A1 |
Cinnamoyl amino acid compounds and a use thereof, which relate to the fields of medicinal chemistry and pharmacotherapeutics, and specifically relate to cinnamoyl amino acid compounds having inducible nitric oxide synthase (iNOS) inhibit...
|
WO/2021/189143A1 |
There are provided isotope-enriched compounds containing stable heavy isotope-enriched amide functional groups for modulating the pharmacokinetic profile, metabolic profile, and/or delivery efficiency of a drug or prodrug, as well as its...
|
WO/2021/187992A1 |
The present invention relates to the synthesis of capsaicin derivatives, specifically to the synthesis of 6-heptyne derivatives of capsaicin.
|
WO/2021/184082A1 |
A method of detecting the presence of fentanyl or a fentanyl analogue in a sample which comprises contacting the sample with a 1,2 naphthoquinone (such as 1,2-naphthoquinone itself) in a solvent, preferably acetonitrile, and observing a ...
|
WO/2021/184123A1 |
A method of treating a coronavirus infection involves administering an inhibitor of the Neu1 sialidase – G protein-coupled receptor - Matrix metalloproteinase 9 (Neu1-GPCR-MMP9) signaling platform, in particular administering intraveno...
|
WO/2021/180874A1 |
The present invention provides a method for preparing a benzamide compound, and belongs to the technical field of organic synthesis. The method for preparing a benzamide compound provided by the present invention comprises the following ...
|
WO/2021/180655A1 |
The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and/or preventing e.g. autoimmune, immunological, rheumatology, vascul...
|
WO/2021/179553A1 |
The present invention relates to the use of an N-benzylbenzamide compound or a salt thereof, which are represented by formula (I) and formula (II), as a herbicide. The N-benzylbenzamide compound or the salt thereof is used as a pigment s...
|
WO/2021/183942A1 |
Provided are compounds useful for selectively inhibiting HSP70 isoforms. Also provided are methods of inhibiting HSP70 proteins and methods of treating a disease characterized by overexpression of a HSP70, such as cancer. In particular e...
|
WO/2021/178690A1 |
The invention provides a compound of formula (I): or a salt thereof, wherein A, B, R1, R2, R3 and X have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are usef...
|
WO/2021/177383A1 |
The present invention provides: an asymmetric hydrogenation catalyst comprising a heteropoly acid, a solid-phase support containing a basic group and a platinum-group complex; and a method for producing an optically active amide compound...
|
WO/2021/177297A1 |
The present invention provides a catalyst for use in synthesis of an aromatic amide that can be collected and reused, and addresses the problem of enabling a simple synthesis process in which the amount of a catalyst metal mixed into a p...
|
WO/2021/175670A1 |
The present invention relates to compounds that inhibit the activity of flavivirus.
|
WO/2021/175437A1 |
The present invention relates to compounds that inhibit the activity of flavivirus.
|
WO/2021/178486A1 |
Discloased is processes for producing amide compounds, and their crystalline and salts form. Herein, one of the amide compounds is represented by the following formula (1): which is characterized by an X-ray diffraction (XRD) pattern hav...
|
WO/2021/178841A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and comp...
|
WO/2021/168988A1 |
The present invention provides a synthesis method for a fluorine-containing chiral amine compound. The synthesis method comprises: reacting an amino donor with a fluorine-containing dihydroxy ketal compound under the catalysis of transam...
|
WO/2021/172523A1 |
The present invention is a novel tyrosine derivative for inhibiting the hydrolysis of a polysulfide. A novel tyrosine derivative represented by the following chemical formula. One of a to c represents "OH" and each of the remaining var...
|
WO/2021/171756A1 |
A resin composition according to the present disclosure includes a polyamide resin and a fluorene derivative represented by formula (1). [In the formula, R1 represents a substituent group, k represents an integer of 0-8, R2a, R2b, R2c, a...
|
WO/2021/165339A1 |
The invention relates to a new process for preparing 2H-1,3-benzoxazine-2,4(3H)- dione.
|
WO/2021/159754A1 |
The present invention relates to a method for preparing an lidocaine intermediate α-chloroacetyl-2,6-dimethylaniline and lidocaine without adding additional alkali, belonging to the technical field of organic synthesis. A method for pre...
|
WO/2021/159691A1 |
An N,N-diethyl-10-undecenamide, a preparation method therefor, and a use thereof in repelling mosquitos. An N,N-Diethyl-10-undecenamide, the chemical structure thereof being as shown in formula I. The compound features a simple synthesis...
|
WO/2021/147622A1 |
The present invention belongs to the technical fields of organic synthesis and heterogeneous catalysis, and specifically relates to a method for preparing a formamide compound by catalyzing carbon dioxide hydrogenation with a porous mate...
|
WO/2021/149900A1 |
The present invention relates to: a disubstituted adamantyl derivative or a pharmaceutically acceptable salt thereof, and an anticancer pharmaceutical composition and a kit containing same as an active ingredient. The disubstituted adama...
|
WO/2021/149051A1 |
The present invention provides compounds and herbicidal compositions comprising thereof. Further, use of herbicidal compositions or kit for controlling plant growth is also provided.
|
WO/2021/146386A1 |
The present disclosure provides, inter alia, bivalent small molecules and methods for treating or ameliorating the effects of a disease, such as long QT syndrome, or cystic fibrosis, in a subject, using the bivalent small molecules discl...
|
WO/2021/142186A1 |
Discloased is a pharmaceutical composition comprising: an active ingredient of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof: (I); and one or more excipient selected from the group consisting of a bin...
|
WO/2021/136808A1 |
The present invention relates to conjugates and pharmaceutically acceptable salts thereof, reagents, intermediates, methods for the synthesis of said conjugates, pharmaceutical compositions comprising said conjugates and the use of said ...
|
WO/2021/128648A1 |
The present invention relates to a method for preparing oxamide from dimethyl oxalate, comprising: 1) mixing a dimethyl oxalate stream, a methanol raw material stream and a liquid ammonia stream to perform an ammonolysis reaction to prov...
|
WO/2021/132365A1 |
Provided is a method for producing a highly polymerizable N-vinyl carboxylic acid amide monomer by efficiently purifying N-vinyl carboxylic acid amide. The method for producing a highly polymerizable N-vinyl carboxylic acid amide monom...
|
WO/2021/132364A1 |
Provided is a method with which it is possible to purify N-vinylcarboxamide efficiently and produce a highly polymerizable N-vinylcarboxamide monomer. This method for producing a highly polymerizable N-vinylcarboxamide monomer is chara...
|
WO/2021/132363A1 |
Provided is a method whereby an N-vinyl carboxylic acid amide can be efficiently refined to manufacture a highly polymerizable N-vinyl carboxylic acid amide monomer. This method for manufacturing a highly polymerizable N-vinyl carboxyl...
|
WO/2021/132367A1 |
Provided is a method with which it is possible to purify N-vinylcarboxamide efficiently and produce a highly polymerizable N-vinylcarboxamide monomer. This method for producing a highly polymerizable N-vinylcarboxamide monomer is chara...
|
WO/2021/132366A1 |
Provided is a method by which an N-vinylcarboxylic acid amide can be efficiently purified to produce a highly polymerizable N-vinylcarboxylic acid amide monomer. This method for producing a highly polymerizable N-vinylcarboxylic acid a...
|
WO/2021/127743A1 |
The present disclosure relates to substituted hydroxystilbene compounds and derivatives, specifically 2-substituted hydroxystilbene compounds and derivatives, the synthesis of such compounds and their use in therapy.
|
WO/2021/130451A1 |
The invention relates to chemical compounds C that are derivatives of norbixine and have tropism for the eye, and are intended to be used in the treatment of eye diseases in mammals, in particular in the context of altering the retinal p...
|
WO/2021/120982A1 |
The present invention relates to a method for preparing m-phenylenediamine, comprising the following steps: (1) using meta-xylene as a starting material, preparing isophthalamide; (2) reacting the isophthalamide with hypohalite or haloge...
|
WO/2021/120896A1 |
Provided is a preparation method for norbornane dimethylamine, comprising the following steps: a) mixing a compound having a structure shown in a formula (I) with urotropin, an acid and a first solvent, and carrying out a first reaction ...
|
WO/2021/119632A1 |
A trisamide compound has the structure of Formula (I) in which R1, R2, and R3 are independently selected from the group consisting of alkyl groups. A polymer composition comprises a trisamide compound of Formula (I) and a polyolefin poly...
|
WO/2021/119633A1 |
A trisamide compound has the structure of Formula (I) in which R1, R2, and R3 are independently selected from the group consisting of alkyl groups. A polymer composition comprises a trisamide compound of Formula (I) and a polyolefin poly...
|
WO/2021/117609A1 |
The present invention addresses the problem of providing a composition which stably has high polymerizability, and from which an N-vinyl acetamide polymer is produced. An N-vinyl acetamide-containing composition which is characterized ...
|
WO/2021/117658A1 |
Provided is a method for producing an N-vinylacetamide which can prevent raw material gas (vaporized raw material) from being liquefied by re-condensation, suppress the problem of pyrolysis reactor blockage by resin, and enable stable an...
|
WO/2021/110991A1 |
The present invention relates to a contrast agent suitable for ex vivo imaging, particularly of vascular structures and renal tubular structures, and a method for ex vivo imaging. The contrast agent is a polymer comprising monomers M. Th...
|
WO/2021/110076A1 |
The present invention belongs to the field of medicinal chemistry and relates to oxamide derivatives, a preparation method therefor and the use thereof in medicine. In particular, provided is a compound of formula (I) or a stereoisomer, ...
|
WO/2021/103455A1 |
Provided are a synthesis system and method for preparing adiponitrile by means of the amination of adipic acid. The synthesis system comprises an amination reactor and a reaction rectifying column that are connected in sequence; the reac...
|
WO/2021/105906A1 |
The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, and G are as set forth in the specification, as well as to methods f...
|
WO/2021/106947A1 |
Provided are a compound represented by formula (1) or a pharmacologically acceptable salt thereof, and an antitrypanosomal drug containing the same as an active ingredient. In formula (1), X is NH or CH2, R1 is a hydrogen atom, an alkoxy...
|
WO/2021/103457A1 |
The present invention provides a synthetic system and method for preparing hexamethylenediamine by adiponitrile hydrogenation. The synthetic system comprises an adiponitrile preparation device, a microinterface intensifier, a hydrogenati...
|
WO/2021/101903A1 |
The present invention provides benzamide compounds, compositions containing the benzamides, and use of the benzamides for inhibiting androgen receptor (AR) and/or aldo-keto reductase family 1 member C3 (AKR1C3). Also described herein met...
|